Not for publication or presentation A G E N D A CIBMTR WORKING COMMITTEE FOR IMMUNOBIOLOGY Orlando, Florida Wednesday, February 22, 2017, 12:15 pm– 4:45 pm Co-Chair: Michael Verneris, MD, University of Colorado – Denver; Telephone: 303-724-4006; E-mail: [email protected] Co-Chair: Katharina Fleischhauer, MD; Essen University Hospital; Telephone: +49-201-723-4582; E-mail: [email protected] Co-Chair: Katharine Hsu, MD, PhD; Memorial Sloan-Kettering Cancer Center; Telephone: 646-888-2667; E-mail: [email protected] Co-Scientific Dir: Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Research Center Telephone: 206-667-5160; E-mail: [email protected] Co-Scientific Dir: Stephen Spellman, MBS, CIBMTR Immunobiology Research Telephone: 763-406-8334; E-mail: [email protected] Statistical Director: Tao Wang, PhD, CIBMTR Statistical Center Telephone: 414-955-4339; E-mail: [email protected] Statisticians: Michael Haagenson, MS, CIBMTR Statistical Center Telephone: 763-406-8609; E-mail: [email protected] 1. Introduction (M Verneris) 12:15 pm a. Minutes and Overview Plan of Immunobiology Working Committee at 12:20 pm Tandem 2016 (Attachment 1) 2. Published or submitted papers 12:25 pm a. IB08-06 Rocha V, Ruggeri A, Spellman S, Wang T, Sobecks R, Locatelli F, Askar M, Michel G, Arcese W, Iori AP, Purtill D, Danby R, Sanz GF, Gluckman E, Eapen M. Killer cell immunoglobulin-like receptor ligand matching and outcomes after unrelated cord blood transplantation acute myeloid leukemia. Biol Blood Marrow Transplant. 2016 Jul 1; 22(7):1284-1289. doi:10.1016/j.bbmt.2016.04.007. Epub 2016 Apr 16. PMC4915071. b. IB08-08 Goyal RK, Lee SJ, Wang T, Trucco M, Haagenson M, Spellman SR, Veneris M, Ferrell RE. Novel HLA-DP region susceptibility loci associated with severe acute GvHD. Bone Marrow Transplant. doi:10.1038/bmt.2016.210. Epub 2016 Sep 5. c. IB10-01b Gadalla SM, Khincha PP, Katki HA, Giri N, Wong JYY, Spellman S, Yanovski JA, Han JC, De Vivo, Alter BP, Savage SA. The limitations of qPCR telomere length measurement in diagnosing dyskeratosis congenita. Molecular Genetics & Genomic Medicine. 2016 Jul 1; 4(4):475-479. doi:10.1002/mgg3.220. Epub 2016 Mar 20. PMC4947866. 1 Not for publication or presentation d. IB10-01b Gadalla SM, Wang T, Dagnall C, Haagenson M, Spellman SR, Hicks B, Jones K, Katki HA, Lee SJ, Savage SA. Effect of recipient age and stem cell source on the association between donor telomere length and survival after allogeneic unrelated hematopoietic cell transplantation for severe aplastic anemia. Biol Blood Marrow Transplant. 2016 Dec 1; 22(12):2276-2282. doi:10.1016/j.bbmt.2016.09.012. Epub 2016 Sep 15. PMC5116252. e. IB10-04 Arora M, Lee SJ, Spellman SR, Weisdorf DJ, Guan W, Haagenson M, Wang T, Horowitz MH, Verneris MR, Fleischhauer K, Hsu K, Thyagarajan B. Validation study failed to confirm an association between genetic variants in the base excision repair pathway and transplant-related mortality and relapse after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016 Aug 1; 22(8):1531-1532. doi:10.1016/j.bbmt.2016.04.020. Epub 2016 May 4. f. IB12-04 Hoff GA, Fischer JC, Hsu K, Cooley S, Miller JS, Wang T, Haagenson M, Spellman S, Lee SJ, Uhrberg M, Venstrom JM, Verneris MR. Recipient HLA-C haplotypes and miRNA 148a/b binding sites have no impact on allogeneic hematopoietic cell transplantation outcomes. Biol Blood Marrow Transplant. doi:10.1016/ j.bbmt.2016.09.028. Epub 2016 Oct 13. g. IB12-05/RT10-01 Kornblit B, Wang T, Lee SJ, Spellman SR, Zhu X, Fleischhauer K, Müller C, Johansen JS, Vindelov L, Garred P. YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome. Bone Marrow Transplant. doi:10.1038/bmt.2016.192. Epub 2016 Jul 18. h. IB12-06 Bachanova V, Weisdorf DJ, Wang T, Marsh SGE, Trachtenberg E, Haagenson MD, Spellman SR, Ladner M, Guethlein LA, Parham P, Miller JS, Cooley SA. Donor KIR B genotype improves progression-free survival of non-Hodgkin lymphoma patients receiving unrelated donor transplantation. Biol Blood Marrow Transplant. 2016 Sep 1; 22(9):1602-1607. doi:10.1016/j.bbmt.2016.05.016. Epub 2016 May 21. PMC4981536. i. IB13-02 Marino SR, Lee SM, Binkowski TA, Wang T, Haagenson M, Wang H-L, Maiers M, Spellman S, van Besien K, Lee SJ, Karrison T, Artz A. Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task. Bone Marrow Transplant. 2016 Oct 1; 51(10):1342-1349. doi:10.1038/bmt.2016.142. Epub 2016 May 23. PMC5052106. j. IB13-03 Lazaryan A, Wang T, Spellman SR, Wang H-L, Pidala J, Nishihori T, Askar M, Olsson R, Oudshoorn M, Abdel-Azim H, Yong A, Gandhi M, Dandoy C, Savani B, Hale G, Page K, Bitan M, Reshef R, Drobyski W, Marsh SGE, Schultz K, Müller CR, Fernandez-Viña M, Verneris MR, Horowitz MM, Arora M, Weisdorf DJ, Lee SJ. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: A report from the Center for International Blood and Marrow Transplant Research. Haematologica. 2016 Oct 1; 101(10):1267-1274. doi:10.3324/haematol.2016.143271. Epub 2016 May 31. PMC5046657. 2 Not for publication or presentation k. IB13-05 Askar M, Sobecks R, Wang T, Haagenson M, Majhail N, Madbouly A, Thomas D, Zhang A, Fleischhauer K, Hsu K, Verneris M, Lee SJ, Spellman SR and Fernández-Viña M. MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplants (HCT) For Hematological Malignancies: A CIBMTR Study. Biol Blood Marrow Transplant. 2016 Dec 14. pii: S1083-8791(16)30521-3. doi:10.1016/j.bbmt.2016.11.021. l. IB14-03b Lindsley RC, Saber W, Mar B, Medd, Wang T, Haagenson M, Grauman P, Zhu Z, Spellman S, Lee SJ, Verneris M, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL. Prognostic Mutations in Myelodysplastic Syndrome After Stem Cell Transplantation. In press. New Engl J Med. m. IB10-01c Gadalla SM, Ballew BJ, Haagenson M, Spellman S, Hicks B, Alter BP, Zhu B, Zhou W, Yeager M, Wang T, Fleischhauer K, Hsu K, Verneris M, Freedman N, Lee SJ, Savage SA. Germline Mutations in Marrow Failure Predisposition Genes in Patients Receiving Unrelated Donor Hematopoietic Cell Transplant for Severe Aplastic Anemia. Submitted. J Clin Invest. n. IB12-02B Fleischhauer K, Ahn KW, Wang H-L, Zito L, Crivello P, Müller C, Verneris M, Shaw BE, Pidala J, Oudshorn M, Lee SJ and Spellman SR. Directionality of non-permissive HLA-DPB1 T-cell epitope group mismatches in 8/8 matched unrelated donor hematopoietic cell transplantation. Submitted. Leukemia. o. IB12-03 Madbouly A, Wang T, Haagenson M, Paunic V, Vierra-Green C, Fleischhauer K, Hsu KC, Verneris MR, Majhail NS, Lee SJ, Spellman SR and Maiers Investigating the association of genetic admixture and donor/recipient genetic disparity with transplant outcomes In press. Biol Blood Marrow Transplant. p. IB15-06a Gadalla SM, Wang T, Loftus D, Friedman L, Dagnall C, Haagenson M, Spellman SR, Buturovic L, Blauwkamp M, Shelton J, Fleischhauer K, Hsu KC, Verneris MR, Krstajic D, Hicks B, Jones K, Lee SJ, Savage SA. Donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. Submitted. J Clin Oncol. 3. Research repository update and accrual tables (S Spellman) (Attachment 2) 12:25 pm 4. Future/proposed studies and discussion 12:35 pm a. Voting guidelines (Hsu K) b. PROP1612-05 The impact of HLA-DPB1 levels of expression on clinical outcomes of HCT (M Askar/M Fernandez-Viña) – (Attachment 3) c. PROP1611-158 Identification of genomic markers of post hematopoietic cell transplantation (HCT) outcomes in patients with myelofibrosis (MF): A pilot study (W Saber/S Gadalla) – (Attachment 4) d. PROP1611-41 Donor-recipient NK cell determinants associated with survival in JMML after hematopoietic stem cell transplantation (DA Lee/HG Rangarajan) (Attachment 5) Dropped proposals (due to overlap with current studies) 3 Not for publication or presentation a. PROP1608-02 Outcomes following umbilical cord blood transplantation for inherited metabolic disorders: do allele-level HLA matching characteristics matter? b. PROP1611-80 Using donor characteristics and matching at low expression loci to identify optimal 7of 8 HLA matched unrelated adult donors Dropped proposals (due to limited populations) a. PROP1611-37 Do hypo-methylating agents following HLA C1/C2 mismatched or HLA/KIR mismatched transplantation improve clinical outcome in acute myeloid leukemia? Dropped proposals (due to feasibility/lack of samples) a. PROP1611-164 Insulin-like growth factor 1 and outcome after myeloablative allogeneic HSCT KIR/Haploidentical studies a. Discussion about current numbers, sample availability, and planning for future studies (Attachment 6) i. PROP1610-18 Role of KIR ligand mismatches for transplant outcomes in T-cell replete, non-myeloablative haploidentical transplants, inferring KIR ligand mismatches from HLA-A, -B, and -C locus typing mismatches: a CIBMTR registry analysis ii. PROP1611-36 Impact of KIR ligand mismatches on clinical outcomes following haploidentical stem cell transplantation iii. PROP1612-04 KIR and HLA Allotypes and Donor NK Alloreactivity in HLA- Haploidentical Transplantation 5. Studies in progress (Attachment 7) 1:50 pm NK/KIR 1:50 pm (Chair: K Hsu) R02-40/R03-63 Acquisition of natural killer cell receptors in recipients of unrelated transplant (J Miller/E Trachtenberg) Ongoing – update b. R04-74 Functional significance of killer cell immunoglobulin-like receptor genes in HLA- matched and mismatched unrelated HCT (K Hsu) Ongoing – update c. IB15-02 Natural killer cell genomics and outcomes after allogeneic transplantation for chronic lymphocytic leukemia (V Bachanova, JS Miller, D Weisdorf, S Cooley) Sample typing – no update d.